New hope for myeloma patients: daratumumab combo shows promise without transplant
NCT ID NCT04656951
First seen Mar 11, 2026 · Last updated May 17, 2026 · Updated 9 times
Summary
This study tests a drug combination including daratumumab as the first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. After initial therapy, patients receive maintenance treatment until the disease returns, then they are re-treated with daratumumab. The goal is to see how well this approach controls the cancer and improves remission rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Cologne
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.